Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy

Breast Cancer Research and Treatment

Volumn 122, Issue 2, 2010, Pages 585-590

  Blaes, Anne H ^a   Gaillard, Philippe ^b   Peterson, Bruce A ^a   Yee, Douglas ^a   Virnig, Beth ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Angiotensin converting; Cardiomyopathy; Chemotherapy; Doxorubicin; Enzyme inhibitors; Predictors

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRASTUZUMAB; ANTINEOPLASTIC ANTIBIOTIC;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CHILD; CONTROLLED STUDY; FEMALE; HEART EJECTION FRACTION; HEART PROTECTION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; SARCOMA; SCHOOL CHILD; SIDE EFFECT; UNITED STATES; UTERUS CANCER; BREAST NEOPLASMS; CASE CONTROL STUDY; CHEMICALLY INDUCED; DRUG EFFECTS; ECHOGRAPHY; HEART DISEASES; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHILD; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; LOGISTIC MODELS; LYMPHOMA; MALE; MIDDLE AGED; MINNESOTA; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; YOUNG ADULT;

EID: 77955664697     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0730-5     Document Type: Article

References (42)

1. Lopez M, Vici P, Di Lauro K et al (1998) Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16:86-92.
2. Moore S (2001) Drug-induced congestive heart failure in breast cancer survivors. Clin Excell Nurse Pract 5:129-133.
3. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
4. Machida U, Kami M, Hirai H (1998) Treatment of intermediategrade and high-grade non-hodgkin's lymphoma. N Engl J Med 339:1476.
5. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242.
6. Akhtar S, Maghfoor I (2002) Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med 346:1830-1831.
7. Swain SM (1999) Doxorubicin-induced cardiomyopathy. N Engl J Med 340:654.
8. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905.
9. Lefrak EA, Pitha J, Rosenheim S et al (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32(3):302-314.
10. Hayek ER, Speakman E, Rehmus E (2005) Acute doxorubicin cardiotoxicity. N Engl J Med 352:2456-2457.
11. McKillop J, Bristow M, Goris M et al (1983) Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 106:1048-1056.
12. Ritchie J, Singer J, Thorning D (1980) Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer 46:1109-1116.
13. Paulides M, Kremers A, Stohr W et al (2006) Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer 46(4):489-495.
14. Bleyer WA (1990) The impact of childhood cancer on the United States and the world. CA Cancer J Clin 40:355-367.
15. Hershman DL, McBride RB, Eisenberger A et al (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26(19):3159-3165.
16. Coccaro M, Gallucci G (2008) Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer. J Clin Oncol 26(19):3288.
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717.
18. Boucek RJ Jr, Steele A, Miracle A et al (2003) Effects of angiotensin- converting enzyme inhibitor on delayed-onset doxorubicininduced cardiotoxicity. Cardiovasc Toxicol 3:319-329.
19. Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481.
20. Granger CB (2006) Prediction and prevention of chemotherapyinduced cardiomyopathy: can it be done? Circulation 114:2432-2433.
21. Hatake K, Miura Y (1996) Angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 347:1485.
22. Iqbal M, Dubey K, Anwer T (2008) Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 60(3):382-390.
23. Dunn FG, Oigman W, Ventura HO et al (1984) Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 53:105-108.
24. Wang LX, Ideishi M, Yahiro E et al (2001) Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury. Hypertens Res 24:179-187.
25. Ibrahim MA, Ashour OM, Ibrahim YF et al (2009) Angiotensinconverting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 60:373-381.
26. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA (2001) Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 414:71-78.
27. Iqbal M, Dubey K, Anwer T, Ashish A, Pillai K (2008) Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Res 60:382-390.
28. Toko H, Oka T, Zou Y, Sakamoto M et al (2002) Angiotensin II type Ia receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 25:597-603.
29. Seidman A, Hudis C, Pierri MK et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5): 1215-1221.
30. Swain S, Whaley F, Gerber M et al (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1332.
31. Seymour L, Bramwell V, Moran LA (1999) Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Cancer Prev Control 3(2):145-159.
32. Nakamae H, Tsumura K, Terada Y et al (2005) Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104:2492-2498.
33. Jensen BV, Skovsgaard T, Nielsen SL (2002) Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13(5):699-709.
34. Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48(11):2258-2262.
35. Sardão VA, Oliveira PJ, Holy J et al (2009) Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother Pharmacol 64(4):811-827.
36. Fazio S, Palmieri EA, Ferravante B et al (1998) Doxorubicininduced cardiomyopathy treated with carvedilol. Clin Cardiol 21(10):777-779.
37. Tallaj JA, Franco V, Rayburn BK et al (2005) Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24(12):2196-2201.
38. Naidu MU, Kumar KV, Mohan IK et al (2002) Protective effect of Gingko biloba extract against doxorubicin-induced cardiotoxicity in mice. Indian J Exp Biol 40(8):894-900.
39. Sung RY, Huang GY, Shing MK et al (1997) Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol 60(3):239-248.
40. Steinherz LJ, Steinherz PG, Tan CT et al (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266(12):1672-1677.
41. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431-1439.
42. Meinardi MT, van Veldhuisen DJ, Gietema JA et al (2001) Prospective evaluation of early cardiac damage induced by epirubicin- containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19(10):2746-2753.